On the use of [18F]DOPA as an imaging biomarker for transplanted islet mass

Authors:

Abstract
Islet transplantation is being developed as a potential cure for patients with type 1 diabetes. There is a need for non-invasive imaging techniques for the quantification of transplanted islets, as current transplantation sites are associated with a substantial loss of islet viability. The dopaminergic metabolic pathway is present in the islets; therefore, we propose Fluorine-18 labeled l-3,4-dihydroxyphenylalanine ([18F]DOPA) as a biomarker for transplanted islet mass.

This publication has 22 references indexed in Scilit: